Program
1st Day Program 2nd Day Program
December 3, 2009
| 08:45-09:00 | Welcome Address by the Ambassador of France H.E. Pierre Vimont |
| 09:00-09:20 | Introduction and Welcome Prof Fabien CALVO, MD, PhD Deputy Director at the French National Cancer Institute (INCA), Director of the Multi-Institutions Institute, thematic “Cancer”, French National Institute of Medical Research (INSERM) |
| 09:20-09:40 | Introduction and Welcome Prof Mauro FERRARI Professor and Chairman, Department of Nanomedicine and Biomedical Engineering (nBME) Professor of Internal Medicine, Division of Cardiology, The University of Texas Health Science Center |
| 09:40-10:10 | Elizabeth Mansfield, PhD Senior Genomoics Advisor Office of the Chief Scientist U.S. Food and Drug Administration Lecture: FDA's perspective relative to the Validation of biomarkers (to be confirmed) >>> Questions and answers |
|
10:15-10:45 |
Dr Susan Windham-Bannister, PhD President and CEO Massachusetts Life Sciences Center lecture: Will be last minute determined >>> Questions and answers |
| 10:50-11:00 | COFFEE BREAK |
| 11:00-11:30 | Prof Pierre LAURENT-PUIG, MD, PhD Professor at the Paris Descartes University Medical School Lecture: Biomarkers of Response to Anti EGFR Therapy in Colorectal Cancer >>> Questions and answers |
| 11:35-12:05 | Prof Naomi J. HALAS, PhD Professor, Department of Physics and Astronomy, Department of Biomedical Engineering, Department of Chemistry, Rice University, Houston, TX, USA Director, Laboratory for Nanophotonics, Rice University, Houston, TX, USA Stanley C. Moore Professor in Electrical and Computer Engineering, Rice University, Houston, TX, USA Lecture: Light-based nanomedicine for cancer: merging diagnostics and drug-free therapeutics >>> Questions and answers |
| 12:10-12:40 | Dr Pierre CHAURAND, PhD Associate Professor, VICC Member Vanderbilt University Medical Center Lecture: Imaging mass spectrometry: state of the technology and clinical potentials >>> Questions and answers |
| 12:45-14:00 | LUNCH |
| 14:00-14:30 | Prof Jessica ZUCMAN, MD, PhD Professor of Medicine, Oncology, University Paris Descartes, Hopital Européen Georges Pompidou, Head of the INSERM laboratory, “Functional genomic of solid tumors” in Paris Lecture: Molecular classification of Hepatocarcinoma (HCC): new insights and interest in clinical practice >>> Questions and answers |
| 14:35-15:05 | Dr Franck PEREZ, PhD Research Director at CNRS in France Group leader in the Cell Biology Section at the Curie Institute (Paris, France) Lecture: Conformation-specific antibodies selected by an antibody phage display approach >>> Questions and answers |
| 15:10-15:40 | Prof Bernard BIHAIN, MD Chairman of GENCLIS Lecture: Increased transcription infidelity in cancer cells deregulates innate humoral immunity and provides novel method for early stage diagnosis >>> Questions and answers |
| 15:45-16:00 | COFFEE BREAK |
| 16:00-16:30 | Prof Ralph BRADSHAW, PhD Professor, Department of Pharmaceutical Chemistry, University of California (UCSF), San Francisco, CA, and Deputy Director, Mass Spectrometry Facility, UCSF, San Francisco, CA lecture: Will be last minute determined >>> Questions and answers |
| 16:35-17:05 | Prof Gilles THOMAS, MD, PhD Fondation Synergie-Lyon-Cancer Professor of Medical Genetics at University LYON 1 Lecture: Genome wide association studies for cancer predisposition >>> Questions and answers |
| 17:10-17:40 | Dr François BERGER, MD, PhD Head of the Cell Biology Department in Joseph Fourier University Medical School Head of the “Brain Nanomedicine” group in the INSERM, Research Center U 836 (ex U 318), Head of the clinico-biologal Neuro-oncology unit in Grenoble university hospital lecture: A Theranostic micro-nanotechnology strategy opening the exploration of « tissue-poly-omic » inaccessible territories >>> Questions and answers |
| 17:45 | CONCLUSION |
December 4, 2009
| 07:30-07:45 | Registration and breakfast |
| 07:45-08:00 | Presentation of Mérieux Alliance and its strategy for innovation by Christian Bréchot, Vice-president of scientific and medical affairs |
| 08:00-08:15 | Presentation of Mérieux Développement, private equity firm by François Valencony, Managing director |
| 08:15-08:25 |
Daniel Wang, Oranoxis Inc. Oral Fluid Taesting for Therapeutic Cancer Drug Monitoring |
| 08:25-08:35 |
Benjamin A. Belinka, Actinobac Biomed, Inc. Leukotoxin for the Diagnosis and Treatment of Autoimmune Diseases |
| 08:35-08:45 |
David T. Wong, UCLA School of Dentistry Salivary Diagnostics for Molecular Oncology Applications |
| 08:45-08:55 |
Virginie Clément, University Hospital of Geneva An effort to enhance the development of biomarkers for brain tumors using a unique technology developed by our laboratory and Stemergie |
| 08:55-09:05 |
Matthew Gombrich, Viridis Diagnostics A Novel Rapid Theranostic Test for Severe Bacterial Pneumonia – Moving Theranostics into the Acute Care Setting to Reduce Broad Spectrum Prescribing of Antibiotics |
| 09:05-09:15 |
Frederic Bienvenu, Dana-Farber Cancer Institute Transcription-Nuclear Export Coupling as a New Cancer Diagnosis-Prognosis and Therapeutic Target |
| 09:15-09:25 |
Victor V Levenson, Rush U Medical Center DNA methylation patterns of antiestrogen-resistant breast cancer |
| 09:25-09:35 |
Fiorenzo Omenetto, Tufts University A new green/sustainable platform for global delivery of medical and pharmaceutical products based on silk |
| 09:35-09:45 |
Carol A. Kumamoto, Tufts University Novel diagnostics for invasive candidiasis |
| 09:45-09:55 |
Cavigiolio Giorgio, Children’s Hospital Oakland Research Institute A New Biomarker of HDL Functionality for Cardiovascular Disease Risk Assessment |
| 09:55-10:05 |
Christophe Egles, Tufts University High throughput human tissue-equivalent platforms: new research tools for translational discovery and development |
| 10:05-10:45 | Coffee break and discussions around candidates’Posters |
| 10:45-10:55 |
M. Philip N Tsichlis, Tufts Medical Center The diagnostic and therapeutic applications of the imbalance between Akt1 and Akt2 in human Cancer |
| 10:55-11:05 |
Joel Berniac / Ban-An Khaw, Akrivis Technologies LLC Akrivis Technologies LLC Development and Applications of Novel Ultrasensitive Diagnostics and Targeted Therapeutics for the Early Detection and Treatment of Cancer. |
| 11:05-11:15 |
Nancy Hurtado-Ziola / Mark Hattendorf, Gc-Free, Inc. Dietary Red Meat, Neu5Gc and Inflammation: Diagnosing Risk and Recommending Therapy |
| 11:15-11:25 |
Pascal Puchois, Trans-Hit Biomarkers A unique and highly efficient validation platform to accelerate the development of diagnostic biomarkers and theranostics in infectiology |
| 11:25-11:35 |
Thomas Gauthier, Philips Ultrasound R&D Novel non-invasive imaging biomarkers for cardiovascular disease and oncology |
| 11:35-11:45 |
Al Tofighi, ETEX Corporation New Class of nano-crystalline Combination Biomaterial for Minimally Invasive Treatment of Vertebral Compression Fractures. |
| 11:45-11:55 |
David N. Ku / Larry J. Anderson, Emory School of Medicine A New Pneumonia Theranostic Device – PneumoniaCheck |
| 11:55-12:05 |
Catherine A. McCarty, Marshfield Clinic Research Foundation Pharmacogenetics of beta blockers and prostanoid analogues in glaucoma |
| 12:05-12:15 |
Fabien Campagne, Weill Medical College of Cornell University Commercial Platform for Dependable Predictive Model Development and Evaluation |
| 12:15-12:25 |
Alex Turjman Why and when aneurysms form and grow |
| 12:25-12:35 |
Robert K. Prud’homme / Robert H. Austin, Princeton University New generation of imaging and labeling agents based on nanocrystalline Upconversion Phosphors (UCP) |
| 12:35-12:45 |
Amit Banerjee, College of Pharmacy, Wayne State University Protein Ubiquitination Enzymes as Theranostics Targets for your call: "Theranostics and Biology: Know-How Challenges, Applications & Breakthroughs” |
| 12:45-12:55 |
Peter Libby, Brigham and Women's Hospital Theranostic nanotechnology approach to treating atherosclerotic plaques |
| 12:55-14:30 | Cocktail and lunch |
